JP2020511152A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511152A5
JP2020511152A5 JP2019552175A JP2019552175A JP2020511152A5 JP 2020511152 A5 JP2020511152 A5 JP 2020511152A5 JP 2019552175 A JP2019552175 A JP 2019552175A JP 2019552175 A JP2019552175 A JP 2019552175A JP 2020511152 A5 JP2020511152 A5 JP 2020511152A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
set forth
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019552175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511152A (ja
Filing date
Publication date
Priority claimed from DE102017106305.6A external-priority patent/DE102017106305A1/de
Application filed filed Critical
Publication of JP2020511152A publication Critical patent/JP2020511152A/ja
Publication of JP2020511152A5 publication Critical patent/JP2020511152A5/ja
Priority to JP2023044130A priority Critical patent/JP7787119B2/ja
Priority to JP2025159746A priority patent/JP2026021299A/ja
Withdrawn legal-status Critical Current

Links

JP2019552175A 2017-03-23 2018-03-23 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法 Withdrawn JP2020511152A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023044130A JP7787119B2 (ja) 2017-03-23 2023-03-20 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法
JP2025159746A JP2026021299A (ja) 2017-03-23 2025-09-26 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762475329P 2017-03-23 2017-03-23
DE102017106305.6A DE102017106305A1 (de) 2017-03-23 2017-03-23 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
DE102017106305.6 2017-03-23
US62/475,329 2017-03-23
PCT/EP2018/057482 WO2018172533A2 (en) 2017-03-23 2018-03-23 T cell receptors and immune therapy using the same against prame positive cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023044130A Division JP7787119B2 (ja) 2017-03-23 2023-03-20 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法

Publications (2)

Publication Number Publication Date
JP2020511152A JP2020511152A (ja) 2020-04-16
JP2020511152A5 true JP2020511152A5 (enExample) 2021-04-30

Family

ID=61899213

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019552175A Withdrawn JP2020511152A (ja) 2017-03-23 2018-03-23 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法
JP2023044130A Active JP7787119B2 (ja) 2017-03-23 2023-03-20 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法
JP2025159746A Pending JP2026021299A (ja) 2017-03-23 2025-09-26 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023044130A Active JP7787119B2 (ja) 2017-03-23 2023-03-20 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法
JP2025159746A Pending JP2026021299A (ja) 2017-03-23 2025-09-26 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法

Country Status (31)

Country Link
US (2) US11236145B2 (enExample)
EP (2) EP4450087A3 (enExample)
JP (3) JP2020511152A (enExample)
KR (2) KR20240151870A (enExample)
CN (2) CN110494160B (enExample)
AU (2) AU2018240501B2 (enExample)
BR (1) BR112019019523A2 (enExample)
CA (1) CA3056493A1 (enExample)
CL (1) CL2019002645A1 (enExample)
CO (1) CO2019011688A2 (enExample)
CR (1) CR20190482A (enExample)
DK (1) DK3600409T3 (enExample)
ES (1) ES2986840T3 (enExample)
FI (1) FI3600409T3 (enExample)
HR (1) HRP20241228T1 (enExample)
HU (1) HUE068640T2 (enExample)
IL (2) IL310552B2 (enExample)
LT (1) LT3600409T (enExample)
MA (1) MA47932B1 (enExample)
MD (1) MD3600409T2 (enExample)
MX (2) MX2019011260A (enExample)
MY (1) MY199084A (enExample)
PE (1) PE20191493A1 (enExample)
PH (1) PH12019502151A1 (enExample)
PL (1) PL3600409T3 (enExample)
PT (1) PT3600409T (enExample)
RS (1) RS65924B1 (enExample)
SG (1) SG11201908023YA (enExample)
SI (1) SI3600409T1 (enExample)
SM (1) SMT202400351T1 (enExample)
TW (1) TWI799922B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
JP7054418B2 (ja) 2017-11-08 2022-04-13 ビオンテック ユーエス インコーポレイテッド T細胞を製造する組成物及び方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3670530A1 (en) * 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
GB2613715B (en) * 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
TWI867324B (zh) 2019-05-08 2024-12-21 美商百歐恩泰美國公司 T細胞製備組合物及方法
JP7686571B2 (ja) * 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法
KR20220029584A (ko) * 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
CU20220029A7 (es) * 2019-11-18 2023-01-16 BioNTech SE Receptores de tcr de prame
BR112022014461A2 (pt) * 2020-01-24 2022-09-13 Regeneron Pharma Antígeno preferencialmente expresso em receptores de células t de melanoma (prame) e métodos de uso dos mesmos
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス,アイエヌシー. がんおよび関連する悪性腫瘍の治療のためにt細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022017435A1 (zh) * 2020-07-22 2022-01-27 信达生物制药(苏州)有限公司 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230190807A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating
CN113789304B (zh) * 2021-10-14 2023-03-31 深圳大学总医院 高亲和力tcr及其应用
CN113817044B (zh) * 2021-10-14 2023-10-13 深圳大学总医院 T细胞受体、相关工程化细胞及其应用
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
KR20250018168A (ko) 2022-04-28 2025-02-04 이매틱스 유에스 인코포레이티드 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
CN115073584B (zh) * 2022-05-07 2023-10-20 溧阳瑅赛生物医药有限公司 一种特异性识别prame抗原肽的tcr及其应用
CN117986350B (zh) * 2023-02-23 2024-08-16 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
RU2578009C2 (ru) 2013-05-08 2016-03-20 Закрытое акционерное общество "ЕВРОГЕН" Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
AU2016230828B2 (en) 2015-03-10 2020-10-22 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Prame肽專一性類t細胞受體抗體
CN106084036A (zh) 2015-11-02 2016-11-09 广州市香雪制药股份有限公司 识别prame抗原短肽的t细胞受体
CN106478809B (zh) 2015-11-06 2018-06-01 广东香雪精准医疗技术有限公司 识别prame抗原短肽的tcr
CN106519019B (zh) 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN106831978B (zh) 2015-12-04 2020-05-26 中国科学院广州生物医药与健康研究院 识别prame抗原的t细胞受体
CN106699874B (zh) 2016-03-29 2018-06-05 广东香雪精准医疗技术有限公司 识别prame抗原短肽的t细胞受体
JP6989138B2 (ja) 2016-06-17 2022-01-05 メディジーン イミュノテラピーズ ゲーエムベーハー T細胞受容体及びその使用
DE102017106305A1 (de) * 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers

Similar Documents

Publication Publication Date Title
JP2020529830A5 (enExample)
CN114072427B (zh) 抗dll3嵌合抗原受体及其用途
JP2020500523A5 (enExample)
HRP20241228T1 (hr) T stanični receptori i imunološka terapija uporabom istih protiv pram pozitivnih karcinoma
JP2019536430A5 (enExample)
JP2023139070A5 (enExample)
JP2022543387A5 (enExample)
RU2017121326A (ru) Общие легкие цепи и способы их применения
JP2016505635A5 (enExample)
JP2020525032A5 (enExample)
JP2014534242A5 (enExample)
WO2016180982A1 (en) T cell recruiting polypeptides based on cd3 reactivity
JP2014526898A5 (enExample)
JP2020512019A5 (enExample)
JP2016537966A5 (enExample)
JP2013538057A5 (enExample)
JP2019521641A5 (enExample)
JP2023515223A5 (enExample)
JP2015504306A5 (enExample)
JP2016538830A5 (enExample)
JP2017531427A5 (enExample)
JP2013527761A5 (enExample)
JP2023540526A5 (enExample)
JP2013532968A5 (enExample)
JP2010511388A5 (enExample)